308 related articles for article (PubMed ID: 24799308)
21. C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?
Alexander MP; Fervenza FC; De Vriese AS; Smith RJH; Nasr SH; Cornell LD; Herrera Hernandez LP; Zhang Y; Sethi S
J Nephrol; 2016 Apr; 29(2):203-209. PubMed ID: 26187133
[TBL] [Abstract][Full Text] [Related]
22. Dense deposit disease and C3 glomerulopathy.
Barbour TD; Pickering MC; Terence Cook H
Semin Nephrol; 2013 Nov; 33(6):493-507. PubMed ID: 24161036
[TBL] [Abstract][Full Text] [Related]
23. C3 glomerulopathy: Understanding an ultra-rare complement-mediated renal disease.
Heiderscheit AK; Hauer JJ; Smith RJH
Am J Med Genet C Semin Med Genet; 2022 Sep; 190(3):344-357. PubMed ID: 35734939
[TBL] [Abstract][Full Text] [Related]
24. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
Noris M; Donadelli R; Remuzzi G
Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
[TBL] [Abstract][Full Text] [Related]
25. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
[TBL] [Abstract][Full Text] [Related]
26. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy.
Hawfield A; Iskandar SS; Smith RJ
Am J Kidney Dis; 2013 May; 61(5):828-31. PubMed ID: 23391537
[TBL] [Abstract][Full Text] [Related]
27. Complement inhibition in C3 glomerulopathy.
Nester CM; Smith RJ
Semin Immunol; 2016 Jun; 28(3):241-9. PubMed ID: 27402056
[TBL] [Abstract][Full Text] [Related]
28. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G
Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
[TBL] [Abstract][Full Text] [Related]
29. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
[TBL] [Abstract][Full Text] [Related]
30. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
31. Liver factor B silencing to cure C3 glomerulopathy: Evidence from a mouse model of complement dysregulation.
Zanchi C; Locatelli M; Corna D; Cerullo D; Fishilevich E; Desai D; Rottoli D; Donadelli R; Noris M; Zoja C; Remuzzi G; Benigni A
Mol Immunol; 2023 Sep; 161():25-32. PubMed ID: 37481826
[TBL] [Abstract][Full Text] [Related]
32. Validation of a Histologic Scoring Index for C3 Glomerulopathy.
Caravaca-Fontán F; Trujillo H; Alonso M; Díaz-Encarnación M; Cabello V; Ariceta G; Quintana LF; Marco H; Barros X; Ramos N; Rodríguez-Mendiola N; Cruz S; Fernández-Juárez G; Rodríguez E; de la Cerda F; Pérez de José A; López I; Fernández L; Pérez Gómez V; Ávila A; Bravo L; Lumbreras J; Allende N; Sanchez de la Nieta MD; Olea T; Melgosa M; Huerta A; Miquel R; Mon C; Fraga G; de Lorenzo A; Draibe J; González F; Shabaka A; Illescas ML; Calvo C; Oviedo V; Da Silva I; Goicoechea de Jorge E; Caravaca F; Praga M;
Am J Kidney Dis; 2021 May; 77(5):684-695.e1. PubMed ID: 33359150
[TBL] [Abstract][Full Text] [Related]
33. C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum.
Al-Ghaithi B; Chanchlani R; Riedl M; Thorner P; Licht C
Pediatr Nephrol; 2016 Nov; 31(11):2079-86. PubMed ID: 27008643
[TBL] [Abstract][Full Text] [Related]
34. Characterization of C3 in C3 glomerulopathy.
Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
[TBL] [Abstract][Full Text] [Related]
35. Outcome of C3 glomerulopathy patients: largest single-centre experience from South Asia.
Kumar A; Nada R; Ramachandran R; Rawat A; Tiewsoh K; Das R; Rayat CS; Gupta KL; Vasishta RK
J Nephrol; 2020 Jun; 33(3):539-550. PubMed ID: 31820418
[TBL] [Abstract][Full Text] [Related]
36. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
[TBL] [Abstract][Full Text] [Related]
37. C3 glomerulopathy.
Servais A; Noël LH; Frémeaux-Bacchi V; Lesavre P
Contrib Nephrol; 2013; 181():185-93. PubMed ID: 23689580
[TBL] [Abstract][Full Text] [Related]
38. Humanized C3 Mouse: A Novel Accelerated Model of C3 Glomerulopathy.
Devalaraja-Narashimha K; Meagher K; Luo Y; Huang C; Kaplan T; Muthuswamy A; Halasz G; Casanova S; O'Brien J; Peyser Boiarsky R; McWhirter J; Gartner H; Bai Y; MacDonnell S; Liu C; Hu Y; Latuszek A; Wei Y; Prasad S; Huang T; Yancopoulos G; Murphy A; Olson W; Zambrowicz B; Macdonald L; Morton LG
J Am Soc Nephrol; 2021 Jan; 32(1):99-114. PubMed ID: 33288630
[TBL] [Abstract][Full Text] [Related]
39. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy.
Zhang Y; Nester CM; Holanda DG; Marsh HC; Hammond RA; Thomas LJ; Meyer NC; Hunsicker LG; Sethi S; Smith RJ
J Am Soc Nephrol; 2013 Nov; 24(11):1820-9. PubMed ID: 23907509
[TBL] [Abstract][Full Text] [Related]
40. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.
Sethi S; Fervenza FC; Zhang Y; Zand L; Vrana JA; Nasr SH; Theis JD; Dogan A; Smith RJ
Kidney Int; 2012 Aug; 82(4):465-73. PubMed ID: 22673887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
